Navigation Links
Agios Pharmaceuticals' founders author Science review on cancer metabolism
Date:5/21/2009

Cambridge, MA May, 21, 2009 Agios Pharmaceuticals, the first biopharmaceutical company focused on discovering and developing novel cancer metabolism drugs, announced that the leading scientific journal Science has published a review article, "Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation," authored by two of its founders, Lewis C. Cantley, Ph.D., Director of the Cancer Center at Beth Israel Deaconess Medical Center and Professor of Systems Biology and Craig B. Thompson, M.D., Director, Abramson Cancer Center, University of Pennsylvania, and one of its scientific advisors, Matthew Vander Heiden, M.D., Ph.D., Instructor of Medicine, Dana Farber Cancer Institute and Harvard Medical School.

"As this review highlights, there is an incredible opportunity in front of us to bring together decades of independent cancer and metabolic scientific research into an integrated approach to novel cancer therapies," said Dr. Vander Heiden, Agios scientific advisor. "It is exciting to see the broad scientific engagement that is driving this field rapidly forward to ultimately provide new options for physician and their patients."

Cancer metabolism is a new and exciting field of biology that represents a breakthrough understanding of how cancer cells become addicted to using more nutrients than normal cells to ensure their survival and growth. The new understanding of a fundamental mechanism of cancer growth and survival represents a powerful Achilles' heel to target this deadly disease.

The Science review article summarizes the current state of the emerging biological field of cancer metabolism and suggests that "a better understanding of anabolic cellular metabolism and how growth control impacts its regulation may lead to new targets and improved therapy for human cancer." The review, which provides a meta-analysis of the field, highlights key advancements ranging from Otto Warburg's discovery in 1929, that cancer cells utilize sugar differently than normal cells, to a 2008 study published in the journal Nature showing that cancer cells 'switch on' the same highly active metabolizing enzymes as those found in fetal cells to promote rapid growth. This latter finding explains why cancer cells are able to divide and grow better than normal cells.

The vision of Agios is to lead the development and translation of cancer metabolism biology and decades of metabolic biochemistry into novel cancer therapeutics that will make a difference for patients. To date, Agios has put in place a world-class scientific team of more than 40 people, built a fully integrated cell metabolism platform within the largest research laboratory dedicated to cancer metabolism and created an emerging product development pipeline of novel Cancer Metabolism drugs.

"The Agios team, pipeline, platform and business strategy that we have built in a short time is exclusively focused on developing a deep biological understanding of the nexus of cancer and metabolism as the key driver behind where, when and how to cripple and kill a cancer cell," said Michael Su, Ph.D., Agios co-founder and Vice President, Drug Discovery. "This Science review, along with many other recent scientific advancements, continues to highlight the significance of the field and Agios' unique ability and position to lead the therapeutic exploration of cancer metabolism."


'/>"/>

Contact: Kathryn Morris
kathryn@kmorrispr.com
845-635-9828
Yates Public Relations
Source:Eurekalert

Related medicine news :

1. ReBuilder Medical Technologies, Inc. Announces UK Demand for Safe Molluscum Contagiosum Treatment Leads to Distribution Agreement with UFFE Medical, LTD. Expected 10% Sales Increase.
2. ReBuilder Medical Technologies, Inc. Announces Revolutionary Electronic Zapper Said to Destroy Molluscum Contagiosum Pathogen
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
6. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
7. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
8. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
9. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
10. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
11. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , ... June 26, 2016 , ... On June 10-11, ... of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, ... the city’s history as home to some of the world’s leading providers of cereal ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... PawPaws ... a new product that was developed to enhance the health of felines. The formula ... , The two main herbs in the PawPaws Cat Kidney Support Supplement ...
(Date:6/26/2016)... , ... June 26, 2016 , ... ... once they have been diagnosed with endometriosis. These women need a treatment plan ... require a comprehensive approach that can help for preservation of fertility and ultimately ...
(Date:6/25/2016)... , ... June 25, 2016 , ... Austin residents seeking ... American College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical ... effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, ... Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms ... Final Cut Pro X . Simply select a ProHand generator and drag it above ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... CHAPEL HILL, N.C. , June 24, 2016 ... in healthcare decisions and regulators/payers have placed more ... this new environment, patient support programs in the ... support for patients, medications. Consequently, pharmaceutical companies are ... to ensure they are providing products and services ...
(Date:6/24/2016)... 2016 Research and Markets ... Electronics 2015-2025: Applications, Technologies, Forecasts" report to ... In-Mold Electronics, Smart Skin, Structural Health Monitoring, Composite ... Structural electronics involves electronic and/or electrical components and ... dumb structures such as vehicle bodies or conformally ...
(Date:6/24/2016)... PUNE, India , June 24, 2016 ... "Pen Needles Market by Type (Standard Pen Needles, Safety ... 12mm), Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase ... published by MarketsandMarkets, This report studies the market for ... is expected to reach USD 2.81 Billion by 2021 ...
Breaking Medicine Technology: